FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
R. Angelo de Claro(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Haw-Jyh Chiu(United States Food and Drug Administration), Donghao Lu(Center for Drug Evaluation and Research), Julie Bullock(Center for Drug Evaluation and Research), Robert Justice(United States Food and Drug Administration), Shwu‐Luan Lee(Center for Drug Evaluation and Research), Elimika Pfuma(United States Food and Drug Administration), Ali Al‐Hakim(Center for Drug Evaluation and Research), Nicole Verdun(Center for Biologics Evaluation and Research), Ann T. Farrell(Center for Drug Evaluation and Research), Bahru Habtemariam(Center for Drug Evaluation and Research), Lei Nie(Center for Drug Evaluation and Research), Yun Wang(Yunnan Agricultural University), Chai‐Ni Chang(Center for Drug Evaluation and Research), Robert C. Kane(United States Food and Drug Administration), Haleh Saber(United States Food and Drug Administration), Karen M. McGinn(Center for Drug Evaluation and Research), Margaret E. Brower(Center for Drug Evaluation and Research), Edvardas Kaminskas(United States Food and Drug Administration)
Cited by 165
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k